A Double-Blind, Randomized, Crossover Study to Assess the Abuse Potential of Intranasal Cebranopadol Compared to Oxycodone and Placebo in Healthy, Nondependent Recreational Opioid Users (CPDD 2025) - Jun 9, 2025 - Pres time: Jun 16, 2025; 01:45 PM - 03:00 PM; Location: Grand Ballroom B, Fifth Floor; "Crushed cebranopadol had significantly lower intranasal abuse potential compared with crushed oxycodone, a Schedule II opioid, in nondependent, recreational opioid users. The onset of drug liking and pharmacokinetics was notably delayed with intranasal cebranopadol vs. intranasal oxycodone."
Clinical • Late-breaking abstract • Addiction (Opioid and Alcohol) • CNS Disorders
|
|
Joseph Grieco; Glen Apseloff; Angela Eakin; Ben Vaughn; Marc Lesnick; James Hackworth; Khyati Mehta; Megan Shram
|